We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This data provides information about the number and types of applications that HM Land Registry completed in August 2024.
How to use a quasi-experimental study to evaluate your digital health product.
How to use a case-control study to evaluate your digital health product.
How to use a cost utility analysis to evaluate your digital health product.
How to use an interrupted time series to evaluate your digital health product.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 20 September, approved the new medicine fruquintinib (Fruzaqla) to treat adult patients with metastatic colorectal cancer (CRC). It is used when other treatments have not worked.
How to use A/B testing to evaluate your digital health product.
Compare different evaluation approaches and choose an appropriate method.
Guidance for businesses and organisations holding EU trade marks at the end of the transition period.
How to use a cost benefit analysis to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).